This brand name is authorized in Nigeria.
The drug AVROCID contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
5QB0T2IUN0 - ALUMINUM HYDROXIDE
|
|
Aluminium hydroxide is a slow-acting antacid. It is used to provide symptomatic relief in gastric hyperacidity. In addition, the antipeptic and demulcent activity of aluminium hydroxide helps to protect inflamed gastric mucosa against further irritation by gastric secretions. |
|
2
|
UNII
NBZ3QY004S - MAGNESIUM HYDROXIDE
|
|
Magnesium hydroxide is practically insoluble in water and solution is not effected until the hydroxide reacts with hydrochloric acid in the stomach to form magnesium chloride. Its neutralising action is almost equal to that of sodium bicarbonate. When the dose is in excess of that required to neutralise the acid the intragastric pH may reach pH 8 or 9. Acid rebound following magnesium hydroxide is clinically insignificant. Magnesium hydroxide has an indirect cathartic effect resulting from water retention in the intestinal lumen. |
|
3
|
UNII
92RU3N3Y1O - DIMETHICONE
|
|
Simethicone is a chemically inert, non-systemic gastric defoaming agent that works by altering the elasticity of interfaces of mucus-embedded bubbles in the gastrointestinal tract. The gas bubbles are thus broken down or coalesced and in this form gas is more easily eliminated through eructation or passing flatus. |
|
This drug has been approved in Nigeria as follows:
| Identifier | Form | Presentation | Description | Approval |
|---|---|---|---|---|
| A11-100460 | Suspension | Avrocid Suspension Sugar Free SUSP 468.1 mg/5 mL; 100 mg/5 mL; 125 mg/5 mL 200 mL (in amber coloured bottle) | Oral suspension. A white coloured, flavoured suspension | 23/02/2023 |
| A11-100461 | Suspension | Avrocid Suspension Banana Flavour SUSP 468.1 mg/5 mL; 100 mg/5 mL; 125 mg/5 mL 200 mL (in amber coloured bottle) | Oral suspension. A greenish yellow coloured, flavoured suspension | 23/02/2023 |
| A11-100462 | Suspension | Avrocid Suspension Strawberry Flavour SUSP 468.1 mg/5 mL; 100 mg/5 mL; 125 mg/5 mL 200 mL (in amber coloured bottle) | Oral suspension. A pink coloured, flavoured suspension | 23/02/2023 |
| A4-4711 | Suspension | Avrocid Suspension SUSP 468.1 mg/5 mL; 100 mg/5 mL; 125 mg/5 mL 200 mL (in amber coloured bottle) | Oral suspension | 28/09/2020 |
| B4-4704 | Chewable tablet | Avrocid Tablets TAB_CHEW 300 mg; 25 mg; 10 mg | Chewable tablet | 07/05/2021 |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| A02AF02 | Ordinary salt combinations and antiflatulents | A Alimentary tract and metabolism → A02 Drugs for acid related disorders → A02A Antacids → A02AF Antacids with antiflatulents |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| NG | Registered Drug Product Database | A11-100460, A11-100461, A11-100462, A4-4711, B4-4704 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.